GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

For people living with psoriasis who also carry a diagnosis of obesity or type 2 diabetes (T2D), a drug class already reshaping cardiovascular and metabolic medicine may offer a meaningful additional benefit: reduced skin disease severity and lower systemic inflammation.¹ A narrative review published in Frontiers in Immunology synthesized the growing body of evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs) in psoriatic disease and found that while the data in psoriasis are encouraging, the evidence base for psoriatic arthritis (PsA) remains thin.

Metabolic Comorbidities Drive the Rationale for GLP-1RA Research

Psoriasis affects an estimated 2% to 3% of the global population and is closely tied to metabolic syndrome, cardiovascular disease, insulin resistance, and T2D. Approximately 30% of people with psoriasis eventually develop PsA, an inflammatory arthropathy affecting peripheral joints, entheses, and the axial skeleton. Obesity has been shown to attenuate responsiveness to biologic therapies in PsA, and insulin resistance appears to play an active role in sustaining joint inflammation rather than simply accompanying it.

Researchers from the University of Modena and Reggio Emilia and the University of Ferrara, Italy, sought to consolidate available clinical evidence on GLP-1RAs in psoriatic disease and examine the pathophysiological rationale for their use, with particular attention to early PsA as a potential window for intervention.

Liraglutide and Semaglutide Demonstrated Consistent Skin Improvements

Most clinical evidence the review identified centered on liraglutide and semaglutide in people with psoriasis and comorbid T2D or obesity. In a randomized controlled trial of 25 patients with psoriasis and T2D, those assigned to liraglutide (1.8 mg/day) experienced greater reductions in Psoriasis Area and Severity Index (PASI) scores than controls receiving conventional therapy, along with significant decreases in skin IL-17, IL-23, and TNF-α expression.

Another open-label randomized trial of semaglutide (1 mg/week) in 31 people with psoriasis and T2D reported significant reductions in serum IL-6 and C-reactive protein alongside improvements in PASI scores, BMI, and LDL cholesterol. Across multiple studies, improvements in skin disease appeared at least partially independent of weight loss, pointing toward direct immunomodulatory activity.

These conclusions about the evidence gaps in psoriatic disease are not isolated. A November 2025 scoping review published in Inflammation Research independently evaluated available data on GLP-1RAs across the full spectrum of psoriatic disease, covering both psoriasis and PsA.² That analysis similarly identified cardiometabolic comorbidities—including obesity, T2D, and cardiovascular disease—as central to the rationale for investigating these agents in psoriatic populations. While evidence supporting GLP-1RA use in psoriasis had grown meaningfully, data in PsA remained limited and largely observational. The independent review reached a parallel conclusion: GLP-1RAs showed potential for dual metabolic and anti-inflammatory benefit in psoriatic disease, but higher-quality prospective trials are needed before their role in clinical practice can be fully defined.

PsA Evidence Remains Limited to a Single Small Study

Evidence for GLP-1RAs specifically in people with PsA was considerably more sparse.¹ Only 1 clinical study directly evaluated GLP-1RA use in the PsA population. That study enrolled 10 adults with obesity and PsA treated with liraglutide (3 mg/day). Participants demonstrated improvements in minimal disease activity scores, along with reductions in body mass index, waist circumference, glycemia, lipid levels, and C-reactive protein. Disease duration was not reported, and participants were not characterized as having early PsA.

Two larger ongoing trials—TOGETHER-PsA (NCT06588296) and TOGETHER AMPLIFY-PsA (NCT06864026)—are evaluating ixekizumab with and without tirzepatide in people with active PsA who have overweight or obesity and are expected to generate more robust data on joint and metabolic outcomes.

Study Limitations Temper Interpretation

The authors acknowledged important constraints. The review was narrative rather than systematic, precluding formal meta-analytic conclusions. Most included studies enrolled people with obesity or T2D specifically, limiting generalizability to the broader psoriasis and PsA population. Methodologically disentangling weight-loss-mediated effects from direct anti-inflammatory effects of GLP-1RAs also remained challenging. Notably, no published study has specifically targeted early PsA populations, a critical gap the review identified.

The authors observed that "early-stage disease may represent an optimal treatment window for maximizing therapeutic effects," while stressing that the concept requires validation in prospective trials designed specifically for that population.

Researchers Call for Dedicated Early PsA Trials

The review underscored that future studies should prioritize well-characterized early PsA cohorts, incorporate metabolic phenotyping, and evaluate potential synergistic effects when GLP-1RAs are combined with established biologics. Long-term assessment of cardiovascular outcomes, musculoskeletal progression, and optimal timing of initiation were also identified as key unanswered questions.

References

1. Ciancio G, Maranini B, Sandri G, et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Front Immunol. 2026;17:1744308. doi:10.3389/fimmu.2026.1744308

2. Buonanno S, Gaggiano C, Terribili R, Cantarini L, Frediani B, Gentileschi S. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflammation Research. 2025;74(1):167. doi:10.1007/s00011-025-02140-2